These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 26118713)

  • 21. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts.
    Teicher BA; Menon K; Alvarez E; Shih C; Faul MM
    Invest New Drugs; 2002 Aug; 20(3):241-51. PubMed ID: 12201487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway.
    Chang MC; Chen CA; Hsieh CY; Lee CN; Su YN; Hu YH; Cheng WF
    Biochem J; 2009 Dec; 424(3):449-58. PubMed ID: 19747165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting.
    Lu H; Li B; Kang Y; Jiang W; Huang Q; Chen Q; Li L; Xu C
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):175-81. PubMed ID: 16718469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.
    Hu L; Hofmann J; Holash J; Yancopoulos GD; Sood AK; Jaffe RB
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6966-71. PubMed ID: 16203789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of the chemotherapeutic effects of a propadiene compound on malignant ovarian cancer cells.
    Li S; Yang L; Wang J; Liang F; Chang B; Gu H; Wang H; Yang G; Chen Y
    Oncotarget; 2016 Aug; 7(35):57145-57159. PubMed ID: 27494891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Smac peptide potentiates TRAIL- or paclitaxel-mediated ovarian cancer cell death in vitro and in vivo.
    Mao HL; Pang Y; Zhang X; Yang F; Zheng J; Wang Y; Liu P
    Oncol Rep; 2013 Feb; 29(2):515-22. PubMed ID: 23151974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. JD enhances the anti-tumour effects of low-dose paclitaxel on gastric cancer MKN45 cells both in vitro and in vivo.
    Wang C; Wang R; Zhou K; Wang S; Wang J; Shi H; Dou Y; Yang D; Chang L; Shi X; Liu Y; Xu X; Zhang X; Ke Y; Liu H
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):971-982. PubMed ID: 27620208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A tumor-penetrating recombinant protein anti-EGFR-iRGD enhance efficacy of paclitaxel in 3D multicellular spheroids and gastric cancer in vivo.
    Sha H; Li R; Bian X; Liu Q; Xie C; Xin X; Kong W; Qian X; Jiang X; Hu W; Liu B
    Eur J Pharm Sci; 2015 Sep; 77():60-72. PubMed ID: 25998561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.
    Taylor SA; Marrinan CH; Liu G; Nale L; Bishop WR; Kirschmeier P; Liu M; Long BJ
    Gynecol Oncol; 2008 Apr; 109(1):97-106. PubMed ID: 18237771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma.
    Jagadish N; Fatima R; Sharma A; Devi S; Suri V; Kumar V; Suri A
    Tumour Biol; 2018 May; 40(5):1010428318773652. PubMed ID: 29745297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models.
    Lengyel E; Litchfield LM; Mitra AK; Nieman KM; Mukherjee A; Zhang Y; Johnson A; Bradaric M; Lee W; Romero IL
    Am J Obstet Gynecol; 2015 Apr; 212(4):479.e1-479.e10. PubMed ID: 25446664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ultrasound-mediated destruction of oxygen and paclitaxel loaded dual-targeting microbubbles for intraperitoneal treatment of ovarian cancer xenografts.
    Luo T; Sun J; Zhu S; He J; Hao L; Xiao L; Zhu Y; Wang Q; Pan X; Wang Z; Chang S
    Cancer Lett; 2017 Apr; 391():1-11. PubMed ID: 28043912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effects of DCC gene on cell growth and chemosensitivity of ovarian epithelial carcinoma cells].
    Zhuang RJ; Li PL; Yu HW; Li HM
    Zhonghua Fu Chan Ke Za Zhi; 2007 May; 42(5):334-8. PubMed ID: 17673047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidermal growth factor receptor blockade potentiates apoptosis mediated by Paclitaxel and leads to prolonged survival in a murine model of oral cancer.
    Holsinger FC; Doan DD; Jasser SA; Swan EA; Greenberg JS; Schiff BA; Bekele BN; Younes MN; Bucana CD; Fidler IJ; Myers JN
    Clin Cancer Res; 2003 Aug; 9(8):3183-9. PubMed ID: 12912971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.
    Tong L; Chen W; Wu J; Li H
    Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antrodia camphorata induces apoptosis and enhances the cytotoxic effect of paclitaxel in human ovarian cancer cells.
    Liu FS; Yang PY; Hu DN; Huang YW; Chen MJ
    Int J Gynecol Cancer; 2011 Oct; 21(7):1172-9. PubMed ID: 21897275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma.
    Myoung H; Hong SD; Kim YY; Hong SP; Kim MJ
    Cancer Lett; 2001 Feb; 163(2):191-200. PubMed ID: 11165754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergy between Paclitaxel and Anti-Cancer Peptide PNC-27 in the Treatment of Ovarian Cancer.
    Alagkiozidis I; Gorelick C; Shah T; Chen YA; Gupta V; Stefanov D; Amarnani A; Lee YC; Abulafia O; Sarafraz-Yazdi E; Michl J
    Ann Clin Lab Sci; 2017 May; 47(3):271-281. PubMed ID: 28667027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simultaneous inhibition of the mitogen-activated protein kinase kinase and phosphatidylinositol 3'-kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma.
    Kawaguchi W; Itamochi H; Kigawa J; Kanamori Y; Oishi T; Shimada M; Sato S; Shimogai R; Sato S; Terakawa N
    Cancer Sci; 2007 Dec; 98(12):2002-8. PubMed ID: 17900261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
    Garofalo A; Naumova E; Manenti L; Ghilardi C; Ghisleni G; Caniatti M; Colombo T; Cherrington JM; Scanziani E; Nicoletti MI; Giavazzi R
    Clin Cancer Res; 2003 Aug; 9(9):3476-85. PubMed ID: 12960140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.